These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 23888251)

  • 1. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.
    Wittmann M; Helliwell PS
    Dermatol Ther (Heidelb); 2013 Jun; 3(1):1-15. PubMed ID: 23888251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
    Sakkas LI; Mavropoulos A; Bogdanos DP
    Curr Med Chem; 2017; 24(28):3054-3067. PubMed ID: 28554321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P
    Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.
    Li H; Zuo J; Tang W
    Front Pharmacol; 2018; 9():1048. PubMed ID: 30386231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M; Papp K
    BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase-4 Inhibition in the Management of Psoriasis.
    Crowley EL; Gooderham MJ
    Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
    Schafer PH; Truzzi F; Parton A; Wu L; Kosek J; Zhang LH; Horan G; Saltari A; Quadri M; Lotti R; Marconi A; Pincelli C
    Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
    Schafer PH; Parton A; Capone L; Cedzik D; Brady H; Evans JF; Man HW; Muller GW; Stirling DI; Chopra R
    Cell Signal; 2014 Sep; 26(9):2016-29. PubMed ID: 24882690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
    Picchianti-Diamanti A; Spinelli FR; Rosado MM; Conti F; Laganà B
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the development of phosphodiesterase-4 inhibitors.
    Li G; He D; Cai X; Guan W; Zhang Y; Wu JQ; Yao H
    Eur J Med Chem; 2023 Mar; 250():115195. PubMed ID: 36809706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More than a random association between chronic obstructive pulmonary disease and psoriatic arthritis: shared pathogenic features and implications for treatment.
    Quartuccio L; Sebastiani M; Spinelli FR; Di Marco F; Peluso R; D'Angelo S; Cauli A; Rossini M; Atzeni F
    Expert Rev Clin Immunol; 2022 Sep; 18(9):983-990. PubMed ID: 35881045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M; Papp K
    Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.
    Schett G; Sloan VS; Stevens RM; Schafer P
    Ther Adv Musculoskelet Dis; 2010 Oct; 2(5):271-8. PubMed ID: 22870453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.
    Spadaccini M; D'Alessio S; Peyrin-Biroulet L; Danese S
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28617319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 4 and its inhibitors in inflammatory diseases.
    Jin SL; Ding SL; Lin SC
    Chang Gung Med J; 2012; 35(3):197-210. PubMed ID: 22735051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
    Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
    Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
    Page CP; Spina D
    Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.
    Herrmann FE; Hesslinger C; Wollin L; Nickolaus P
    Front Pharmacol; 2022; 13():838449. PubMed ID: 35517783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast in psoriatic arthritis.
    Schett G
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
    Schafer PH; Parton A; Gandhi AK; Capone L; Adams M; Wu L; Bartlett JB; Loveland MA; Gilhar A; Cheung YF; Baillie GS; Houslay MD; Man HW; Muller GW; Stirling DI
    Br J Pharmacol; 2010 Feb; 159(4):842-55. PubMed ID: 20050849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.